First Monthly Shot for Schizophrenia Wins FDA Approval

For the first time, adults with schizophrenia have a once-monthly injection option that requires no loading doses, no oral pills alongside it, and no waiting around after each shot.

The FDA approved WELTRUZA this week, marking a significant step forward for the 2.1 million Americans living with schizophrenia. This new treatment delivers olanzapine, the most widely prescribed medication for the condition, in a convenient subcutaneous injection given just once a month.

The approval stems from results of the SOLARIS trial, which showed patients experienced overall symptom improvement, reduced illness severity, and better personal and social functioning. The safety profile matched what doctors already know about oral olanzapine, a medication trusted for more than 30 years.

Here's why this matters: daily pills are hard to stick with long-term. Missing doses can increase the risk of symptoms returning and destabilizing someone's condition, potentially leading to hospitalization or crisis.

WELTRUZA addresses this challenge by eliminating the need for daily medication routines. Patients can get their treatment once a month and go about their day immediately afterward, with no required monitoring period.

The medication will be available in three strengths that correspond to common daily doses of oral olanzapine. Doctors can match the right strength to each patient's needs without complicated dosing schedules or supplemental pills.

The Ripple Effect

When people with schizophrenia can more easily stick with their treatment, the benefits extend far beyond symptom control. Stable treatment means more time with family, better ability to hold jobs, stronger relationships, and greater independence in daily life.

Care partners and family members also benefit from knowing their loved ones are receiving consistent medication. The monthly schedule makes it easier to support someone's treatment journey without the daily stress of pill management.

This approval represents years of patient-centered innovation focused on removing barriers to care. By combining proven medication with novel formulation technology, researchers created a solution that fits real-world challenges people face.

The most common side effects included weight gain, sleepiness, headache, constipation, and injection site reactions, consistent with the oral form of the medication. Only 5% of trial participants stopped treatment due to side effects, matching the placebo group's 4% rate.

WELTRUZA will reach U.S. patients in the coming weeks, offering a new tool for managing this complex condition more effectively.